Lexology September 26, 2023
Morgan, Lewis & Bockius LLP

FDA’s Center for Biologics Evaluation and Research (CBER), the locus of regulating cell and gene therapies among other expanding areas of biotech, is poised for change on a number of important fronts—leadership, significant growth, and plans to address challenging scientific and regulatory issues. With a well-earned reputation of stability, and slow, plodding progress, moments with so many elements in flux at FDA don’t come around often, so it is worth keeping an eye on how these begin to unfold to have a sense of where CBER—central to many of the exciting developments in industry—is headed.


Earlier this year, CBER underwent a reorganization that, most notably, established the Office of Therapeutic Products (OTP) as a “Super-Office” within the center. With...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Biotech venture firms continue ‘recalibration’ in third quarter, Pitchbook report finds
Forbes names 30 under 30 in healthcare
Insilico Medicine Launches First-in-Human Trial for AI-Discovered IBD Drug
How to Choose the Right Distribution Partner
Listen: CRISPR history, biotech struggles, & a big week for deals

Share This Article